# Beijing Daxiang Biotech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-daxiang-biotech-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.daxiangbio.cn
- Total disclosed funding: $16M
- Latest round: Series B (Feb 13, 2026)
- Investors on record: 9

## About

Based in Beijing, China and founded in 2018, Beijing Daxiang Biotech Co., Ltd. operates as a biochip developer that provides Organ-on-a-Chip and Organoid. In August 2020, the company launched the first batch of domestic commercial organ chips. In December 2021, Wuhan Biospecimen Bank Co., Ltd. became the strategic partner of the company. 

In February 2026, Beijing Daxiang Biotech Co., Ltd raised over CNY 100 million in series B funding co-led by new investors Shunxi Fund and E-Town International Industrial Investment.

Beijing Daxiang Biotech Co., Ltd. provides organ chips, organoid for many fields, such as new drug development, disease modeling and individualized precision medicine. Its products are divided into in vitro models, microarray products, devices and kits. Microarray products include high-throughput barrier function organs-on-chips, organoid expansion chip for dynamic culture and high-throughput 3D microchip for organoid culture and drug screening. The company also provides drug discovery, clinical translation and basic research. 

The company generates revenue by doing research, development, sales of its products and providing other related services.

The company will use the series B funding to focus on four strategic directions: AI-driven iteration of organoid chip technology, intelligent manufacturing and upgrading of organoid chip life science instruments, construction of intelligent drug screening and precision medicine platforms, and breakthroughs in digital twin and virtual experiment technologies.

## Funding rounds

- Series B, Feb 13, 2026, $14M — E-Town International Industrial Investment, Shunxi Fund
- Series A, Jul 30, 2021 — CDH Investments, Hongtai Aplus, Furong Capital, Renai Capital
- Series A, May 11, 2021 — CDH Investments, Furong Capital, Jiuyo Capital, Shanghai AppTec, MiraclePlus
- Angel, Nov 18, 2019, $1.4M — Furong Capital, Jiuyo Capital, Shanghai AppTec

## Investors

- Furong Capital (https://capitalatlas.ai/funds/furong-capital) — Angel, Series A
- Jiuyo Capital (https://capitalatlas.ai/funds/jiuyo-capital) — Angel, Series A
- Shanghai AppTec — Angel, Series A
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series A
- MiraclePlus (https://capitalatlas.ai/funds/miracleplus) — Series A
- Hongtai Aplus (https://capitalatlas.ai/funds/hongtai-aplus) — Series A
- Renai Capital (https://capitalatlas.ai/funds/renai-capital) — Series A
- E-Town International Industrial Investment (https://capitalatlas.ai/funds/e-town-international-industrial-investment) — Series B
- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series B